ALK-Abelló (ALK B) Stock Overview
Operates as an allergy solutions company in Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ALK B from our risk checks.
ALK B Community Fair Values
Create NarrativeSee what 28 others think this stock is worth. Follow their fair value or set your own to get alerts.
ALK-Abelló A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 230.20 |
| 52 Week High | DKK 234.40 |
| 52 Week Low | DKK 130.70 |
| Beta | 0.70 |
| 1 Month Change | 9.83% |
| 3 Month Change | 25.79% |
| 1 Year Change | 45.70% |
| 3 Year Change | 127.25% |
| 5 Year Change | 120.50% |
| Change since IPO | 574.08% |
Recent News & Updates
Recent updates
ALK-Abelló A/S (CPH:ALK B) Just Reported And Analysts Have Been Lifting Their Price Targets
Nov 15
Does ALK-Abelló (CPH:ALK B) Have A Healthy Balance Sheet?
Oct 11ALK-Abelló A/S' (CPH:ALK B) Popularity With Investors Is Clear
Jul 23ALK-Abelló (CPH:ALK B) Seems To Use Debt Quite Sensibly
Jun 17Is There An Opportunity With ALK-Abelló A/S' (CPH:ALK B) 24% Undervaluation?
May 04Here's Why ALK-Abelló (CPH:ALK B) Has Caught The Eye Of Investors
Apr 16Here's Why ALK-Abelló (CPH:ALK B) Can Manage Its Debt Responsibly
Mar 12Earnings Update: ALK-Abelló A/S (CPH:ALK B) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Feb 22ALK-Abelló A/S' (CPH:ALK B) Share Price Matching Investor Opinion
Dec 18
Allergy+ Strategy And Neffy Nasal Spray Will Ignite Revenue Growth And Boost Earnings
The Allergy+ strategy and neffy nasal spray deal are expected to create new revenue streams and drive growth from 2025 onward.Results: ALK-Abelló A/S Exceeded Expectations And The Consensus Has Updated Its Estimates
Nov 17Shareholder Returns
| ALK B | DK Pharmaceuticals | DK Market | |
|---|---|---|---|
| 7D | 14.5% | 6.9% | 3.3% |
| 1Y | 45.7% | -54.4% | -33.5% |
Return vs Industry: ALK B exceeded the Danish Pharmaceuticals industry which returned -54.4% over the past year.
Return vs Market: ALK B exceeded the Danish Market which returned -33.5% over the past year.
Price Volatility
| ALK B volatility | |
|---|---|
| ALK B Average Weekly Movement | 4.5% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in DK Market | 9.6% |
| 10% least volatile stocks in DK Market | 2.5% |
Stable Share Price: ALK B has not had significant price volatility in the past 3 months compared to the Danish market.
Volatility Over Time: ALK B's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 2,764 | Peter Halling | www.alk.net |
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mites, grass and tree pollen, ragweed, Japanese cedar, and food.
ALK-Abelló A/S Fundamentals Summary
| ALK B fundamental statistics | |
|---|---|
| Market cap | DKK 50.92b |
| Earnings (TTM) | DKK 1.10b |
| Revenue (TTM) | DKK 6.08b |
Is ALK B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALK B income statement (TTM) | |
|---|---|
| Revenue | DKK 6.08b |
| Cost of Revenue | DKK 2.06b |
| Gross Profit | DKK 4.01b |
| Other Expenses | DKK 2.91b |
| Earnings | DKK 1.10b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.98 |
| Gross Margin | 66.04% |
| Net Profit Margin | 18.11% |
| Debt/Equity Ratio | 2.8% |
How did ALK B perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/15 14:50 |
| End of Day Share Price | 2025/11/14 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ALK-Abelló A/S is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Jesper Ilsoe | Carnegie Investment Bank AB |
| Jesper Ilsøe | DNB Carnegie |